CKPT Checkpoint Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CKPT

Price (delayed)

$1.58

Market cap

$56.38M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.17

Enterprise value

$51.46M

Checkpoint Therapeutics, Inc. ('Checkpoint') is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint is ...

Highlights
CKPT's EPS has surged by 55% year-on-year and by 30% since the previous quarter
The equity has grown by 33% YoY and by 31% from the previous quarter
Checkpoint Therapeutics's revenue has decreased by 46% YoY and by 40% QoQ
CKPT's gross profit is down by 46% YoY and by 40% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.checkpointtx.com
Peers: OMER OMGA

Key stats

What are the main financial stats of CKPT
Market
Shares outstanding
35.69M
Market cap
$56.38M
Enterprise value
$51.46M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
287.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
499.58
Earnings
Revenue
$103,000
EBIT
-$51.85M
EBITDA
-$51.85M
Free cash flow
-$47.59M
Per share
EPS
-$3.17
Free cash flow per share
-$2.54
Book value per share
-$0.55
Revenue per share
$0.01
TBVPS
$0.29
Balance sheet
Total assets
$5.38M
Total liabilities
$18.43M
Debt
$0
Equity
-$13.05M
Working capital
-$13.05M
Liquidity
Debt to equity
0
Current ratio
0.29
Quick ratio
0.27
Net debt/EBITDA
0.1
Margins
EBITDA margin
-50,336.9%
Gross margin
100%
Net margin
-50,336.9%
Operating margin
-50,629.1%
Efficiency
Return on assets
-950%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
-50,336.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CKPT stock price

How has the Checkpoint Therapeutics stock price performed over time
Intraday
6.76%
1 week
10.49%
1 month
-17.71%
1 year
-49.84%
YTD
-31%
QTD
-22.93%

Financial performance

How have Checkpoint Therapeutics's revenue and profit performed over time
Revenue
$103,000
Gross profit
$103,000
Operating income
-$52.15M
Net income
-$51.85M
Gross margin
100%
Net margin
-50,336.9%
The company's operating margin has shrunk by 67% YoY and by 48% QoQ
CKPT's net margin has dropped by 60% since the previous quarter and by 54% year-on-year
Checkpoint Therapeutics's revenue has decreased by 46% YoY and by 40% QoQ
CKPT's gross profit is down by 46% YoY and by 40% from the previous quarter

Growth

What is Checkpoint Therapeutics's growth rate over time

Valuation

What is Checkpoint Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
287.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
499.58
CKPT's EPS has surged by 55% year-on-year and by 30% since the previous quarter
The equity has grown by 33% YoY and by 31% from the previous quarter
Checkpoint Therapeutics's revenue has decreased by 46% YoY and by 40% QoQ
CKPT's price to sales (P/S) is 29% lower than its 5-year quarterly average of 404.9 but 18% higher than its last 4 quarters average of 243.2

Efficiency

How efficient is Checkpoint Therapeutics business performance
CKPT's return on sales has dropped by 60% since the previous quarter and by 54% year-on-year
The return on assets has declined by 31% since the previous quarter

Dividends

What is CKPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CKPT.

Financial health

How did Checkpoint Therapeutics financials performed over time
The total assets is 71% less than the total liabilities
The company's current ratio has surged by 190% QoQ but it fell by 29% YoY
The total assets has soared by 142% from the previous quarter but it has plunged by 60% YoY
CKPT's debt is 100% greater than its equity
The equity has grown by 33% YoY and by 31% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.